Activity | T-50 | T-40 | T-30 | T-20 | T-10 | In-Life Phase | T+10 | T+20 | T+30 | T+40 | T+50 | T+60 | T+70 |
a) Initial planning T-50 | | | | | | | | | | | | | |
b) Confidentiality agreement | | | | | | | | | | | | | |
c) Request for draft quote T-50 | | | | | | | | | | | | | |
d) Approval of draft quote T-45 | | | | | | | | | | | | | |
e) Initial study plan T-30 | | | | | | | | | | | | | |
| 1) Analysis of dose solutions (method and schedule) |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| 4) Test and control article handling and storage |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| 6) Dosing: route of administration, regimen, duration |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| 9) Necropsy/gross pathology |
| | | | | | | | | | | | | |
| 10) Clinical chemistry parameters |
| | | | | | | | | | | | | |
| 11) Histopathology parameters |
| | | | | | | | | | | | | |
| 12) Analysis of data (statistics) |
| | | | | | | | | | | | | |
f) Draft study protocol T-28 | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
g) Set pre-study meeting date (CRO staff) T-28 | | | | | | | | | | | | | |
h) Pre-study Sponsor—CRO meeting (preferably in person, or by video or teleconference) T-14 | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | a) Sponsor company: technical contact, admin contact, other |
| | | | | | | | | | | | | |
| | b) CRO: technical management, study director, QA, admin |
| | | | | | | | | | | | | |
| 2) Review and clarify: protocol, study background, deadlines |
| | | | | | | | | | | | | |
i) Protocol approval T-10 | | | | | | | | | | | | | |
j) Sponsor transfers test article to CRO T-3 | | | | | | | | | | | | | |
k) Sponsor and QA review draft report T+29 to T+50 | | | | | | | | | | | | | |
l) Sponsor receives final report T+60 | | | | | | | | | | | | | |
m) Team review/evaluation with CRO T+70 | | | | | | | | | | | | | |